SANA BIOTECHNOLOGY INC (SANA)
Health Care · Cell therapy and engineered cell therapeutics · NASDAQ
Sana Biotechnology develops engineered cell therapies using proprietary hypoimmune and in vivo CAR T platforms to treat type 1 diabetes, B cell cancers, and autoimmune diseases.
What SANA BIOTECHNOLOGY INC does
Sana Biotechnology is a clinical-stage cell engineering company developing transformative therapeutics through ex vivo and in vivo cell engineering platforms. The company's lead program, SC451, is a hypoimmune platform (HIP)-engineered stem cell-derived pancreatic islet cell therapy for type 1 diabetes designed to achieve normal blood glucose without insulin injections or immunosuppression. Its second major program, SG293, is an in vivo CAR T cell therapy using a fusogen platform to deliver genetic payloads directly to T cells, targeting B cell malignancies and B cell-mediated autoimmune diseases.
Themes: ["Cell therapy / engineered cells","Type 1 diabetes / metabolic disease","CAR T cell therapy","In vivo gene delivery","Immunotherapy / oncology","Autoimmune disease","Regenerative medicine"]
Fundamentals
- Price$3.93 as of 2026-07-09 close
- Market cap$1.1B as of 2026-07-10
- 1-year return+2.3% as of 2026-07-09 close
- ROE-161.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta2.10 as of 2026-07-10
Key risks (from latest filing)
["Clinical and regulatory development timelines are uncertain; SC451 and SG293 are early-stage candidates requiring successful IND filings and Phase 1 trials with no guarantee of safety or efficacy data as planned","Manufacturing and scale-up of cell therapies presents significant technical and operational challenges; ability to produce SC451 and other candidates at commercial scale remains unproven","Substantial ongoing capital requirements with limited revenue; company's future depends on successful development, regulatory approval, and commercialization of product candidates, with no assurance of profitability or sustained funding"]
Competitors & peers
- Vertex Pharmaceuticals (VERX)
- CRISPR Therapeutics (CRSP)
- Sangamo Therapeutics
- Juno Therapeutics
- Gilead Sciences (GILD)
- Novartis (NVS)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.